Apollomics (APLM) Competitors $6.28 -0.32 (-4.78%) As of 01:46 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock APLM vs. CLNN, TPST, GDTC, QTTB, LEXX, CARA, CYTH, CASI, EGRX, and DRRXShould you be buying Apollomics stock or one of its competitors? The main competitors of Apollomics include Clene (CLNN), Tempest Therapeutics (TPST), CytoMed Therapeutics (GDTC), Q32 Bio (QTTB), Lexaria Bioscience (LEXX), Cara Therapeutics (CARA), Cyclo Therapeutics (CYTH), CASI Pharmaceuticals (CASI), Eagle Pharmaceuticals (EGRX), and DURECT (DRRX). These companies are all part of the "pharmaceutical products" industry. Apollomics vs. Clene Tempest Therapeutics CytoMed Therapeutics Q32 Bio Lexaria Bioscience Cara Therapeutics Cyclo Therapeutics CASI Pharmaceuticals Eagle Pharmaceuticals DURECT Apollomics (NASDAQ:APLM) and Clene (NASDAQ:CLNN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, community ranking, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership. Does the MarketBeat Community believe in APLM or CLNN? Clene received 78 more outperform votes than Apollomics when rated by MarketBeat users. Likewise, 81.19% of users gave Clene an outperform vote while only 80.00% of users gave Apollomics an outperform vote. CompanyUnderperformOutperformApollomicsOutperform Votes480.00% Underperform Votes120.00% CleneOutperform Votes8281.19% Underperform Votes1918.81% Is APLM or CLNN more profitable? Apollomics has a net margin of 0.00% compared to Clene's net margin of -8,556.77%. Apollomics' return on equity of 0.00% beat Clene's return on equity.Company Net Margins Return on Equity Return on Assets ApollomicsN/A N/A N/A Clene -8,556.77%-1,106.30%-85.11% Do institutionals & insiders have more ownership in APLM or CLNN? 19.1% of Apollomics shares are owned by institutional investors. Comparatively, 23.3% of Clene shares are owned by institutional investors. 35.3% of Clene shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Does the media refer more to APLM or CLNN? In the previous week, Apollomics and Apollomics both had 2 articles in the media. Clene's average media sentiment score of 0.63 beat Apollomics' score of 0.44 indicating that Clene is being referred to more favorably in the news media. Company Overall Sentiment Apollomics Neutral Clene Positive Which has more volatility & risk, APLM or CLNN? Apollomics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Clene has a beta of 0.46, suggesting that its stock price is 54% less volatile than the S&P 500. Which has higher valuation & earnings, APLM or CLNN? Clene has lower revenue, but higher earnings than Apollomics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioApollomics$1.22M5.67-$172.60MN/AN/AClene$342K73.64-$49.50M-$5.75-0.51 Do analysts rate APLM or CLNN? Apollomics currently has a consensus price target of $200.00, indicating a potential upside of 3,087.25%. Clene has a consensus price target of $50.20, indicating a potential upside of 1,613.31%. Given Apollomics' higher possible upside, research analysts plainly believe Apollomics is more favorable than Clene.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Apollomics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Clene 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17 SummaryClene beats Apollomics on 10 of the 16 factors compared between the two stocks. Get Apollomics News Delivered to You Automatically Sign up to receive the latest news and ratings for APLM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart APLM vs. The Competition Export to ExcelMetricApollomicsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.92M$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E RatioN/A7.3622.6118.58Price / Sales5.67241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book0.136.486.704.26Net Income-$172.60M$143.43M$3.22B$248.31M7 Day Performance0.88%1.69%1.26%1.34%1 Month Performance-10.36%6.58%3.73%3.92%1 Year Performance-85.02%-2.63%15.82%5.33% Apollomics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)APLMApollomics2.0694 of 5 stars$6.28-4.8%$200.00+3,087.3%-84.5%$6.92M$1.22M0.0045Gap DownCLNNClene2.8295 of 5 stars$3.02+0.7%$55.25+1,729.5%-65.6%$25.96M$342,000.00-0.57100Upcoming EarningsTPSTTempest Therapeutics2.0123 of 5 stars$7.11-2.3%$30.00+321.9%-84.2%$25.02MN/A-4.6520Upcoming EarningsGDTCCytoMed Therapeutics2.1498 of 5 stars$2.28-7.3%$5.00+119.3%+12.3%$24.94MN/A0.00N/AGap DownQTTBQ32 Bio2.6728 of 5 stars$2.03-4.2%$24.71+1,117.5%-94.2%$24.76M$-6,651,000.00-0.1439Upcoming EarningsShort Interest ↓News CoverageLEXXLexaria Bioscience2.426 of 5 stars$1.39+0.7%$7.00+403.6%-62.5%$24.41M$525,923.00-2.787Short Interest ↓Analyst RevisionCARACara Therapeutics3.8767 of 5 starsN/A$83.52+∞N/A$24.33M$7.14M-0.2580Analyst ForecastPositive NewsGap DownHigh Trading VolumeCYTHCyclo Therapeutics1.3659 of 5 stars$0.72flat$0.95+31.8%N/A$23.72M$870,725.00-0.809CASICASI Pharmaceuticals3.8505 of 5 stars$1.92-1.0%$4.00+108.3%-15.7%$23.61M$28.54M-0.86180Analyst ForecastEGRXEagle PharmaceuticalsN/A$1.80+11.1%N/A-52.1%$23.38M$257.55M0.00100Analyst ForecastGap DownDRRXDURECT0.8291 of 5 stars$0.74-1.0%N/A-37.5%$23.15M$2.03M-1.2180Analyst ForecastGap Up Related Companies and Tools Related Companies Clene Competitors Tempest Therapeutics Competitors CytoMed Therapeutics Competitors Q32 Bio Competitors Lexaria Bioscience Competitors Cara Therapeutics Competitors Cyclo Therapeutics Competitors CASI Pharmaceuticals Competitors Eagle Pharmaceuticals Competitors DURECT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:APLM) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredBlackrock’s Sending THIS Crypto Higher on PurposeWhile everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Apollomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Apollomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
